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These ﬁndings suggest that host T cells are elicited following
direct recognition of—and co-stimulation by—donor APC. To
address this hypothesis, CD80/86/ mice were transplanted with
C3H.SW BM. Rejection was efﬁcient and equivalent to that in
B6-wt mice. These ﬁndings support the notion that CD80/86
co-stimulation by donor APC’s is sufﬁcient and required to initiate
resistance against donor BM in “naı¨ve” recipients. In contrast,
recipients sensitized to B6 antigens prior to transplant rejected
both B6-wt and CD80/86/ grafts with equal and accelerated
kinetics vs. “naı¨ve” recipients. These observations suggest that B7
co-stimulation is not required to elicit effectors from TM and/or
that indirect presentation could be occurring. To begin examining
CD80/86 expression on donor APC as a potential strategy for
tolerance induction, C3H.SW BMT recipients received a second
transplant of B6 Ly5.1 or B6-gfp TCD-BM. Although prior re-
cipients of B6-wt marrow rejected these second B6 transplants with
accelerated kinetics, prior recipients of CD80/86/ BM rapidly
achieved and maintained multi-lineage Ly5.1 or gfp chimerism.
In total, these results support the notion that in non-myeloablative
MHC-matched allogeneic BMT, donor APC are critical to initi-
ating the T cell barrier response to engraftment. Moreover, the
absence of CD80/86 co-stimulatory molecules on donor APC can
apparently circumvent T cell mediated resistance and may provide
a strategy for the rapid tolerance induction in such transplants.
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LACK OF IMPACT OF COMORBIDITIES ON OUTCOMES OF ALLOGENEIC
STEM CELL TRANSPLANTATION (ASCT) FOR REFRACTORY ACUTE MY-
ELOID LEUKEMIA (AML)/MYELODYSPLASTIC SYNDROME (MDS)
Wong, R.S.; Shahjahan, M.; Alamo, J.; de Lima, M.; Khouri, I.;
Gajewski, J.; Andersson, B.; Champlin, R.; Giralt, S. University of
Texas M. D. Anderson Cancer Center, Houston, TX.
Introduction: Comorbidities may have impact on both survival
and treatment toxicities in several types of malignancies. We have
previously demonstrated that patients with comorbidities have
lower overall and event free survival (OS/EFS) as well as higher
non-relapse mortality (NRM) in patients with AML/MDS patients
in ﬁrst complete remission undergoing ASCT. However, other
studies suggested that concurrent comorbidities have less impact in
groups with the lowest survival rate. We study the impact of
comorbidities on outcomes in patients receiving ASCT for refrac-
tory AML/MDS. Methods: We retrospectively reviewed 135 pa-
tients with refractory AML (n93), MDS (n24) and MDS/AML
(n18) who received ASCT between 1/1998 and 2/2001 at the
University of Texas M.D. Anderson Cancer Center. Charlson
Comorbidity Index (CCI) was used to score comorbid conditions
and CCI score was calculated for each patient as a weighted score
of the patient’s total comorbid conditions. Results: Median age
was 49 years (range 19–75). There were 77 males and 58 females.
Disease status included primary induction failure (n53), ﬁrst
relapse refractory diseases (n49) and patients with more than two
relapses (n33). 55 patients received myeloablative conditioning
regimens including Thiotepa/BU/CY (n29), BU/CY (n19) and
TBI (N7). 80 patients received reduced intensity conditioning
regimens with F-Ara-Ida (n16), FM	 ATG (n43) and F/BU	
ATG or CAMPATH-1H (n21). Analysis was performed com-
paring patients with a CCI score of 0, 1–2 and 2. Univariate
analysis showed that patients with CCI scores of 1–2 and 2 had
no statistically signiﬁcant difference in the overall and event free
survival (OS/EFS) as well as non-relapse mortality (NRM) com-
pared with patients who had a score of 0 (Table 1). Conclusions:
Our results demonstrate that comorbidities have little impact on
the outcomes of patients with refractory AML/MDS. In these
patients, the primary disease, rather than other concurrent dis-
eases, primarily determines survival. Our ﬁndings suggest these
patients can be included in ASCT protocols even if they have
comorbidities. Improvement in disease-speciﬁc survival will trans-
late into improvements in overall survival regardless of coexisting
disease.
Effect of Comorbidity Scores on Allogeneic Transplant Outcomes in
AML/MDS Patients
Outcomes
CCI
Score  0
(N  59)
CCI
Score 1–2
(N  58)
CCI
Score > 2
(N  18)
% OS at 2 years 24 16 39
% EFS at 2 years 20 13 39
% NRM at 1 year 39 52 33
No statistically signiﬁcant difference found in patients with CCI
scores of 1–2 and  2 compared with patients with a score of 0.
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ONCE DAILY INTRAVENOUS (IV) BUSULFAN (BU) CONTAINING PRE-
PARATIVE REGIMENS FOR HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (HSCT): LOW INCIDENCE OF HEPATIC VENO-OCCLUSIVE DIS-
EASE (HVOD) AND IMPROVED EARLY SURVIVAL IN A SINGLE CENTER’S
EXPERIENCE
Benn, H.; Amin, A.; Susan, H.-C.; Kramek, D.; Janbay, N.;
Randhawa, D.; Nath, R. Saint Joseph’s Regional Medical Center, Pater-
son, NJ.
Background: IV Bu has demonstrated similar outcomes but
lower incidence of HVOD when used instead of oral Bu as a
component of preparative regimens for HSCT. The usual dose for
IV Bu is 0.8 mg/kg q 6 h. Once daily IV Bu (3.2 mg/kg/day) has
been successfully combined with Fludarabine in HSCT. There are
very limited and conﬂicting data about the safety of combining
once daily IV Bu with other chemotherapeutic drugs in preparative
regimens. Patients and Methods: Twenty one patients with he-
matological malignancies were identiﬁed in our database who had
undergone once daily IV Bu containing preparative regimens for
HSCT between June 2002 and September 2004. There were 15
males and 6 females. Their median age was 48 (range 19–62) years.
Preparative regimens were as follows: Thiotepa 10 mg/kg/day 1,
Bu 3.2 mg/kg/day  3, Cyclophosphamide (CY) 60 mg/kg/day 
2 for 11 patients; Bu 3.2 mg/kg/day 4, CY 60 mg/kg/day 2 for
7 patients; and Bu 3.2 mg/kg/day  4, Etoposide 60 mg/kg/day 
1 for 3 patients. Sixteen patients underwent allogeneic SCT (un-
related cord blood n10, matched sibling n6) and 4 patients
underwent autologous SCT. GVHD prophylaxis consisted of Ta-
crolimus/Mycophenolate Mofetil (MMF)/Antithymocyte globulin
(ATG) in 10 patients, Cyclosporine A (CsA)/Methotrexate in 5,
and CsA/MMF/ATG in 2 patients. All patients received Ursode-
oxycholic acid and Enoxaparin for prophylaxis of HVOD. Three
patients had undergone a prior SCT (mini allogeneic n2; autol-
ogous n1). Four patients had a history of abnormal liver function
tests. Eleven patients had active disease at the time of HSCT and
4 patients were in  second complete remission. Results: All 20
evaluable patients engrafted with a median time for neutrophil
recovery of 18 (range 9–32) days. One patient died prior to HSCT
because of cardiac toxicity. Seven patients (35%) developed hyper-
bilirubinemia (bilirubin 2 mg/dl) within the ﬁrst 30 days and ten
patients (50%) developed hyperbilirubinemia within ﬁrst 100 days
post transplant with the peak bilirubin being 4.0 and 7.1 mg/dl
respectively. Two patients (10%) had mild HVOD based on the
modiﬁed Seattle Criteria which resolved without any intervention.
Eighteen of the nineteen evaluable patients (94.7%) were surviving
on day 100. Conclusion: Preparative regimens combining once
daily IV Bu along with other alkylating agents or etoposide result
in universal engraftment, a low incidence of HVOD and excellent
early survival.
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LONG-TERM FOLLOW UP OF PATIENTS WHO EXPERIENCED GRAFT
FAILURE POST ALLOGENEIC PROGENITOR CELL TRANSPLANTATION
Rondon, G.; Khouri, I.; Giralt, S.; Chan, K.; McMannis, J.; Champlin,
R.; Shpall, E. University of Texas M.D. Anderson Cancer Center,
Houston, TX.
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Graft failure (GF) is life-threatening complication of allogeneic
transplant (Allo-T). Long-term outcomes of interventions used to
treat this complication have not been extensively studied. We
retrospectively reviewed the long-term survival after GF occurring
at the M.D. Anderson Cancer Center from 1990–2000. Allo-T
recipients were included if they had GF for any of the following
reasons 1) Primary GF (PGF) if pts failed to achieve an ANC
500/l for 3 consecutive days by day 28 post transplant if bone
marrow (BM) or peripheral blood (PBPCs) were the stem cell
source, or 42 days for cord blood (CB); 2) Primary GF with
autologous reconstitution (PGF-AR) if patients recovered hema-
topoiesis without evidence of donor cell engraftment; or 3) Sec-
ondary GF (SGF) if there was a decrease in ANC levels to
500/l
for 3 consecutive days after having achieved engraftment without
disease progression. 68 pts were identiﬁed out of a total of 1750
(4%) allografts performed during that time period. Median age was
37 yrs (range, 4–75); diagnosis included 22 pts with CML or other
myeloproliferative disorders, 27 with acute leukemia, 17 with lym-
phoma or CLL, and 2 with aplastic anemia. 31 pts received cells
from a related donor (15 mismatched in at least 1 allele) while 37
received cells from an unrelated donor. 36 pts received BM, 29
received PB, and 3 received CB. 29 pts had PGF, 9 pts had
PGF-AR and 30 pts had SGF. The 1 and 5 yr overall survival (OS)
for all pts was 31% and 15%. The 1 yr and 5 yr OS for each group
were: PGF-29%/18% PGF-AR 55%/11% and SGF 26%/13%.
The following Table 1 shows the 1 yr and 5 yr survival rates of pts
according to the intervention received. The most common causes
of death were GF (18%) and engraftment but death from infection
(27%) and recurrent/persistent disease (41%). We conclude that
pts who experience GF post allogeneic transplantation can be
successfully treated with a variety of interventions, however, death
from other causes is common. Our data suggest that harvesting
autologous cells for back-up in pts undergoing Allo-T procedures
with high risk of GF is warranted.
Outcomes According to Therapy for GF
None
Growth
Factors
Auto
Back Up
Retrans-
plant
Same Donor
Allo
Back Up
Retrans-
plant
Different
Donor
N 9 19 10 14 9 3
OS @ 1/5 yrs 33%/0% 29%/17% 60%/40% 21%/7% 8%/8% 60%/33%
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OPPORTUNISTIC INFECTIONS ARE THE MAJOR CAUSE OF MORTALITY
AFTER NONMYELOABLATIVE UNRELATED BONE MARROW TRANS-
PLANTATION WITH ALEMTUZUMAB, FLUDARABINE AND MELPHALAN
Carroll, M.P.; BuchBarker, D.; Schwartz, R.; Agha, M.E.; Tompkins,
C.; Baileys, K.; O’Connell, K.; Donnenberg, A.D.; Yeager, A.M. Uni-
versity of Pittsburgh Cancer Institute, Pittsburgh, PA.
Nonmyeloablative (NM) allogeneic (allo) hematopoietic cell
transplantation (HCT) may be effective in patients (pts) at high
risk for morbidity and mortality after conventional myeloablative
HCT. We report the outcome of NM bone marrow transplanta-
tion (BMT) from HLA-matched volunteer unrelated donors
(VUDs) in 14 pts (median age 45 yr; range, 19–58) with relapsed
and/or refractory hematologic malignancies (1 ALL, 3 AML, 3
MDS/AML, 3 Hodgkin’s disease, 2 multiple myeloma, 2 NHL).
Thirteen pts had previous autologous (10 pts) or allo (3 pts) HCT.
The NM regimen included alemtuzumab (20 mg/day 5, days8
through 4), ﬂudarabine (30 mg/m2/day  5, days 7 through
3) and melphalan (140 mg/m2 on day 2), as described by
Kottaridis PD et al, Blood 2000;96:2419 and Chakraverty R et al,
Blood 2002;99:1071. Two pts had primary graft failure (actuarial
probability 16.4%; 95% conﬁdence interval [CI] 0–37.6%). In the
12 evaluable pts, median times to ANC0.5 109/L and platelets
20  109/L were 15 (range, 9–41) and 21 days (range, 15–41),
respectively, after NMBMT. Two pts developed grade I or grade
II acute graft-versus-host disease (GVHD) at 19 and 76 days,
respectively, after NMBMT. The actuarial probability of grade II
or greater GVHD is 9.1% (95% CI 0–26.2%). Two pts developed
extensive chronic GVHD, and one of these pts died with chronic
GVHD-associated pulmonary failure 267 days after NMBMT.
Five pts developed cytomegalovirus (CMV) reactivation, and one
of these pts died with CMV infection at 122 days after NMBMT.
Six pts died with other infections at a median of 74 days (range,
52–209) after NMBMT: 2 adenovirus (1 associated with graft
failure), 2 toxoplasmosis, 1 Aspergillus (associated with graft fail-
ure), and 1 Pseudomonas (associated with chronic GVHD). Actuarial
nonrelapse mortality (NRM) is 60.0% (95% CI 32.6–87.4%), and
infection-associated mortality is 50.0% (95% CI 23.7–76.3%).
Three pts relapsed at 181, 182 and 202 days, respectively, after
NMBMT; actuarial relapse rate is 37.5% (95% CI 4.0–71.0%).
Three pts are alive in remission at 235, 255 and 914 days,
respectively, after NMBMT; actuarial event-free survival (EFS) is
14.3% (95% CI 0–37.4%). Opportunistic infection is the major
cause of NRM and poor EFS in pts with high-risk hematologic
malignancies who undergo VUD NMBMT after alemtuzumab,
ﬂudarabine and melphalan. Efforts to improve immune reconsti-
tution and infection prophylaxis after NMBMT with this regimen
are warranted.
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CALCULATING IV BUSULFAN (IVBU) DOSE USING BODY SURFACE AREA
PREDICTS MEASURED DRUG EXPOSURE MORE ACCURATELY THAN
DOSING IN MG/KG BUT DOES NOT ELIMINATE THE NEED FOR PHAR-
MACOKINETICS (PK) TO OBTAIN DOSING PRECISION
Nance, A.G.; Vaughan, W.P.; Wang, W.; Salzman, D.E. UAB School
of Medicine, Birmingham, AL.
Bu has been shown to be an effective chemotherapeutic agent
against a variety of hematologic diseases when used in high dose
preparative regimens for auto and allo hematopoietic stem cell
transplantation (HSCT), but variation in area under the curve
(AUC) above or below the target range is associated with increased
risk of toxicity or relapse. ivBu minimizes intrapatient variability,
but interpatient variability remains a signiﬁcant problem. The
initial goal of our study was to determine the ability of a test dose
to predict later ivBu levels. Patients are given the ﬁrst of 16 2-hr
infusions of ivBu 48 hours prior to the beginning of the remaining
15 doses given q 6 h. Doses 2–15 are adjusted to achieve a target
AUC based on ﬁrst dose PK. The PK study is performed using a
5-sample limited sampling strategy and a single compartment, ﬁrst
order elimination model in WinNonlin. Using this strategy, more
than 80% of patients achieve an AUC within 10% of the target.
However, due to the expense and time involved in drawing, pro-
cessing, and calculating ivBu levels after a test dose, we sought to
determine if ivBu doses based on any speciﬁc body metric or metric
based formula (BSA) could accurately predict ivBu AUC. Fifty-one
adult patients (aged 18 to 69) from May 2003 to May 2004 receiv-
ing an ivBu containing preparative regimen for allo or auto HSCT
for HD, NHL, AML, ALL, or CML were dosed per the above test
dose strategy. All were given a test dose equal to 0.8 mg per kg for
an average adult weight (70 kg) for a target AUC of 1250 M  min
and proportionately lower doses for lower targets. Using simple
linear regression analysis comparing AUC achieved with dose
given, we sought to determine whether the ﬁxed dose given recal-
culated in mg/m2 (using 3 different formulas), or mg/kg body
weight (actual, ideal, or adjusted ideal) was the best predictor of
AUC achieved. In this comparison mg/m2 yielded an R2 value of
0.58, while the best R2 value using mg/kg was 0.50. Although BSA
predicted for AUC somewhat better than weight alone, neither is
adequate to replace busulfan PK levels at present. In the future we
will look at other factors, which in conjunction with body metrics
may inﬂuence ivBu AUC predictability, including race, gender,
age, BUN, creatinine, ALT, SGOT, and history of hepatic injury
or hepatic risk history. Multivariate linear regression analysis will
be used to determine the best dosing algorithm.
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